Hypertrophy: Clinical Trials

27 trials for Hypertrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed. 27 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 427Completed 27

Follow Hypertrophy: new trials by email Literature Review of Hypertrophy trials Research Report on Hypertrophy

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Empagliflozin and Cardiac Remodelling in People Without Diabetes
Empagliflozin, Placebo - Cardiovascular Diseases, Left Ventricular Hypertrophy
Phase 4CompletedUnity Health Toronto1692021-04-012023-02-17
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
Amlodipine 5mg, Losartan, Losartan and Amlodipine - Aortic Stenosis, Aortic Regurgitation
Phase 4CompletedHanmi Pharmaceutical Company Limited1282018-10-182022-09-15
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
sacubitril/valsatran, valsartan, placebo to valsartan - Heart Failure
Phase 4CompletedNovartis Pharmaceuticals552018-07-052024-01-05
Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients
cardiac MRI, echocardiography with strain, Laboratory tests - Secondary Hyperparathyroidism, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 4CompletedRainer Oberbauer622017-10-012020-06-09
Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
Dapagliflozin, Placebo - Type 2 Diabetes, Left Ventricular Hypertrophy
Phase 4CompletedUniversity of Dundee662017-02-142019-07-09
Antihypertensive Treatment in Masked Hypertension
Allisartan Isoproxil, Placebo - Masked Hypertension
Phase 4CompletedYan Li3202017-02-142025-01-06
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
Valsartan 80 mg - Hypertension Complicated, Hypertrophy, Left Ventricular
Phase 4CompletedTrinity Hypertension & Metabolic Research Institute302017-02-072018-04-11
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696) - Heart Failure, Reduced Ejection Fraction
Phase 4CompletedNovartis Pharmaceuticals1402016-12-162021-10-07
Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants
Everolimus, Mycophenolate mofetil, Tacrolimus - Hypertrophy, Left Ventricular
Phase 4CompletedEdoardo Melilli202016-11-012021-01-08
Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects
Dapagliflozin 10mg, Glibenclamide 5Mg Tablet - Hypertension, Diabetes Mellitus, Type 2
Phase 4CompletedUniversity of Campinas, Brazil162016-07-012018-05-08
MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease
Metformin XL, Placebo - Left Ventricular Hypertrophy, Insulin Resistance
Phase 4CompletedUniversity of Dundee682015-03-012019-04-10
Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?
Allopurinol, Placebo - Hypertension, Hypertrophy, Left Ventricular
Phase 4CompletedUniversity of Dundee722014-09-012019-09-17
Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy
Eplerenone 50 mg Tab - Hypertension,Essential, Obstructive Sleep Apnea
Phase 4CompletedPoznan University of Medical Sciences1252014-07-012017-06-14
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Allopurinol, Placebo (for allopurinol) - End Stage Renal Disease, Left Ventricular Hypertrophy
Phase 4CompletedUniversity of Dundee802013-09-012016-11-04
Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery
Remote ischemic preconditioning at left upper arm, Control group - Patients With Elective Aortic Valve Replacement
Phase 4CompletedYonsei University792013-06-012016-11-22
24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
Everolimus, Tacrolimus, Mycophenolic acid (MPA) - Renal Transplant
Phase 4CompletedNovartis Pharmaceuticals712010-08-012015-12-07
Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis Patients
BCM, control group - Left Ventricular Hypertrophy
Phase 4CompletedEge University1262009-06-012013-09-09
A Clinical Trial of IntensiVE Dialysis
haemodialysis - Renal Replacement Therapy, Renal Dialysis
Phase 4CompletedThe George Institute2002008-05-012019-12-03
Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?
Placebo, Allopurinol - Kidney Disease, Left Ventricular Hypertrophy
Phase 4CompletedA. D. Struthers672008-01-012016-11-03
Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis
post-dilution on-line hemodiafiltration, high flux hemodialysis - End-Stage Renal Disease
Phase 4CompletedErcan OK7822007-01-012013-09-09

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Hypertrophy, Left Ventricular (26)  ·  Hypertension (7)  ·  Kidney Failure, Chronic (6)  ·  Cardiovascular Diseases (4)  ·  Aortic Valve Stenosis (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Dilatation, Pathologic (2)  ·  Heart Failure (2)  ·  Inflammation (2)  ·  Acute Coronary Syndrome (1)  ·  Anemia (1)  ·  Aortic Valve Insufficiency (1)  ·  Arteriovenous Fistula (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Cardiomegaly (1)

Broader conditions

Heart Diseases (27)  ·  Pathological Conditions, Anatomical (27)  ·  Pathological Conditions, Signs and Symptoms (27)  ·  Cardiomegaly (26)  ·  Cardiovascular Diseases (23)  ·  Vascular Diseases (11)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Male Urogenital Diseases (7)  ·  Pathologic Processes (7)  ·  Urogenital Diseases (7)  ·  Urologic Diseases (7)  ·  Chronic Disease (6)  ·  Disease Attributes (6)

Interventions

Valsartan (4)  ·  Allopurinol (3)  ·  Control Groups (2)  ·  Everolimus (2)  ·  Mycophenolic Acid (2)  ·  Tablets (2)  ·  Tacrolimus (2)  ·  dapagliflozin (2)  ·  sacubitril (2)  ·  Amlodipine (1)  ·  Clinical Laboratory Techniques (1)  ·  Dialysis (1)  ·  Echocardiography (1)  ·  Enalapril (1)  ·  Eplerenone (1)

Sponsors

University of Dundee (4)  ·  Ege University (3)  ·  Novartis Pharmaceuticals (3)  ·  A. D. Struthers (1)  ·  AstraZeneca (1)  ·  Edoardo Melilli (1)  ·  Ercan OK (1)  ·  Hanmi Pharmaceutical Company Limited (1)  ·  Janssen Pharmaceutica N.V., Belgium (1)  ·  Medical University of Vienna (1)  ·  Mustafa Kemal University (1)  ·  Novartis (1)  ·  Poznan University of Medical Sciences (1)  ·  Rainer Oberbauer (1)  ·  The George Institute (1)

Countries

Turkey (Türkiye) (5)  ·  United Kingdom (5)  ·  South Korea (3)  ·  United States (3)  ·  Austria (2)  ·  Canada (2)  ·  China (2)  ·  Spain (2)  ·  Australia (1)  ·  Brazil (1)  ·  Finland (1)  ·  New Zealand (1)  ·  Taiwan (1)

Top investigators

Ercan Ok, MD (3)  ·  Allan D Struthers, BSc, MD, FRCP, FESC (1)  ·  Allan D Struthers, BSc, MD, FRCP, FESC, FRSE (1)  ·  Allan Struthers, MD, FRCP (1)  ·  Andrzej Tykarski, Prof (1)  ·  Chim Lang, MD (1)  ·  Chim Lang, MD, FRCP (1)  ·  Christopher Gingles, MBChB (1)  ·  Duk-Hyun Kang (1)  ·  Edoardo Melilli, MD (1)  ·  Ender Hur, MD (1)  ·  Ercan Ok, M.D (1)  ·  Fatih Yalcin, M.D. (1)  ·  Graeme Houston, FRCR, MBBCh (1)

Results publications

PMID 10450601, PMID 10678860, PMID 10908222, PMID 10940788, PMID 11208620, PMID 11422885, PMID 16376782, PMID 17494787, PMID 17921053, PMID 1798888, PMID 18404673, PMID 18458174, PMID 19687350, PMID 20016520, PMID 20411620, PMID 21388319, PMID 22172590, PMID 22306782, PMID 24107724, PMID 25545400, PMID 26208670, PMID 2698218, PMID 27648523, PMID 28151412, PMID 28835229, PMID 2936235, PMID 29424935, PMID 30723975, PMID 31268872, PMID 31299919, PMID 31651370, PMID 31672793, PMID 32578850, PMID 32905623, PMID 32978755, PMID 33825489, PMID 35559350, PMID 35872799, PMID 36335517, PMID 36398903, PMID 37729887, PMID 37932788, PMID 38006908, PMID 38997620, PMID 39091669

NIH funding

2014 (2), 2009 (1), 2016 (1), 2017 (1)